Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management.

@article{Gardam2003AntitumourNF,
  title={Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management.},
  author={Michael Gardam and Edward Clark Keystone and Richard Gordon Menzies and Steven Manners and Emil Skamene and Richard H. Long and Donald C Vinh},
  journal={The Lancet. Infectious diseases},
  year={2003},
  volume={3 3},
  pages={
          148-55
        }
}
Cases of active tuberculosis have been reported worldwide with the use of therapeutic agents that inhibit tumour necrosis factor (TNF) alpha. TNFalpha has a central role in mycobacterial infection and disease. Accordingly, progression of recently acquired tuberculosis infection or reactivation of remotely acquired infection should be expected with the use of anti-TNF agents. The available in-vitro and epidemiological evidence for the two currently approved agents, infliximab and etanercept… CONTINUE READING
BETA

Similar Papers

Citations

Publications citing this paper.
SHOWING 1-10 OF 344 CITATIONS, ESTIMATED 42% COVERAGE

Golimumab and certolizumab: the two new anti-tumor necrosis factor kids on the block.

  • Indian journal of dermatology, venereology and leprology
  • 2010
VIEW 5 EXCERPTS
CITES METHODS & BACKGROUND
HIGHLY INFLUENCED

[Tuberculosis in rheumatoid arthritis patients: the difficulty in making the diagnosis of latent infection].

  • Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia
  • 2010
VIEW 4 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

Tuberculosis in the age of biologic therapy.

VIEW 8 EXCERPTS
CITES BACKGROUND & RESULTS
HIGHLY INFLUENCED

Use of Biologics for Management of Rheumatoid A rthritis

VIEW 6 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

FILTER CITATIONS BY YEAR

2003
2019

CITATION STATISTICS

  • 11 Highly Influenced Citations

  • Averaged 9 Citations per year from 2017 through 2019